{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-020949","form_type":"8-K","ticker":"WINT","cik":"0000946486","company_name":"WINDTREE THERAPEUTICS INC /DE/","filed_at":"2025-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.906879+00:00","generated_at":"2026-05-19T02:24:52.298833+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Windtree receives Nasdaq bid price deficiency letter; delisting risk if hearing not granted by June 25","bullets":["Nasdaq notified Windtree on June 18, 2025 that closing bid price has been below $1.00 for 30 consecutive days.","Company is ineligible for standard 180-day compliance period due to two reverse stock splits >250:1 over prior two years.","Windtree must request a hearing by June 25, 2025, or face suspension/delisting from Nasdaq.","Company intends to request a hearing; automatic stay of delisting pending hearing and any extension granted by Panel.","Common stock continues trading under symbol WINT; no assurance of regaining compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-020949","json":"https://secwatch.observer/filing/0001437749-25-020949.json","markdown":"https://secwatch.observer/filing/0001437749-25-020949.md","text":"https://secwatch.observer/filing/0001437749-25-020949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946486/000143774925020949/0001437749-25-020949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946486/000143774925020949/wint20250620_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T02:24:52.298833+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b09b09ce989299152de51594302619bffec817b4","claim":"WINDTREE THERAPEUTICS INC /DE/ received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv), 5815(4)(A)).","evidence_excerpt":"June 18, 2025, Windtree Therapeutics, Inc. (the “ Company ”) received a deficiency letter (the “ Bid Price Deficiency Letter ”) from the Nasdaq Listing Qualifications Department (the “ Staff ”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“ Minimum Bid Price Requirement ”). Normally, a company would be afforded a 180-cal","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/946486/000143774925020949/0001437749-25-020949-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)(iv), 5815(4)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}